To compare the efficacy and safety profile of topical minoxidil versus low dose oral minoxidil in patients with hairfall and hair thinning due to androgenetic alopecia in tertiary care teaching hospital,Haldwani,Uttarakhand.

Comparative study of efficacy and safety profile of topical minoxidil 5% versus oral minoxidil 2.5 mg in patients with androgenetic alopecia in tertiary care teaching hospital,Haldwani,Uttarakhand. - NIL

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/03/063477

Enrollment

Registered

2024-03-04

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L649- Androgenic alopecia, unspecified

Interventions

Intervention1: Oral minoxidil(2.5mg): Patients will be instructed to take minoxidil tablet 2.5 mg orally once daily every morning after breakfast for 6 months. Control Intervention1: Topical minoxi

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients Of either sex with androgenetic alopecia ( Males- Stage 1 To 4 Of Hamilton-Norwood Scale; Females- Stage 1 And 2 Of Ludwig Scale). 2. Age 18 years and above. 3. Patients In good general health with no evidence of systemic illness. 4. Patients who will give written informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant And lactating women. 2. Children less than 18 years. 3. Patients with systemic disease( PCOD, cardiac patients, epileptic, cancer,etc.) 4. Patients with active scalp infection, seborrheic dermatitis. 5. Patients with alopecia other than androgenetic alopecia. 6. Patients with history of surgical correction of scalp hair. 7. Drug allergy.

Design outcomes

Primary

Measure	Time frame
To compare the efficacy of topical minoxidil 5% versus oral minoxidil 2.5mg in patients with androgenetic alopecia. Timepoint: Patients will be followed up at 0(baseline), 2 months, 4 months and 6 months.	—

Secondary

Measure	Time frame
To study the adverse effect of topical minoxidil & oral minoxidil.Timepoint: Patients will be followed up at 0(baseline), 2 months, 4 months & 6 months.	—

Countries

India

Contacts

Public ContactDr Bhavana Srivastava

Government Medical College,Haldwani

drsbhavana@gmail.com7895782824

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026